Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist

Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.

Coronavirus_Blue
Coronavirus-related concerns are impacting clinical trials

Provention Bio Inc. was the first company to reveal that one of its clinical trials will be halted to prevent infection of study participants with SARS-CoV-2, the virus that causes COVID-19, but at least two other biopharmaceutical firms have delayed initiation of upcoming trials and more studies will be impacted as coronavirus case numbers rise globally.

Oldwick, NJ-based Provention announced on 16 March that it would stop enrolling new patients but continue to treat already enrolled children and adolescents between the ages of 8 and 17 in the Phase III PROTECT study of PRV-301 (teplizumab) in the treatment of newly diagnosed type 1 diabetes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D